Bionomics Ltd
ASX:BNO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bionomics Ltd
Cash & Cash Equivalents
Bionomics Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bionomics Ltd
ASX:BNO
|
Cash & Cash Equivalents
AU$30.7m
|
CAGR 3-Years
53%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
13%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash & Cash Equivalents
$129.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
11%
|
CAGR 10-Years
1%
|
|
|
CSL Ltd
ASX:CSL
|
Cash & Cash Equivalents
$1.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
0%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Cash & Cash Equivalents
AU$20.9m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash & Cash Equivalents
AU$141.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash & Cash Equivalents
AU$120.7m
|
CAGR 3-Years
92%
|
CAGR 5-Years
38%
|
CAGR 10-Years
29%
|
|
Bionomics Ltd
Glance View
Bionomics Ltd. is a clinical stage biopharmaceutical company. The firm is engaged in discovery and development of novel drug candidates focused on the treatment of central nervous system disorders. The firm's segment includes Drug discovery and development and Contract services. Drug discovery and development segment includes discovery, development, and commercialization of compounds to match a target product profile. Contract services segment includes provision of scientific services on a fee for service basis to both external and internal customers. Its product candidates include BNC210, BNC375, BNC101 and BNC105. The BNC210 provides treatment for anxiety disorders, co-morbid anxiety, and depression. The BNC375 is a molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease (AD).The Company operates in three geographical areas, such as Australia, France and United States of America.
See Also
What is Bionomics Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
30.7m
AUD
Based on the financial report for Dec 31, 2022, Bionomics Ltd's Cash & Cash Equivalents amounts to 30.7m AUD.
What is Bionomics Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
13%
Over the last year, the Cash & Cash Equivalents growth was -24%. The average annual Cash & Cash Equivalents growth rates for Bionomics Ltd have been 53% over the past three years , -1% over the past five years , and 13% over the past ten years .
